Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) stock is currently pricing at roughly $0.33. Our analysis shows that the stock is widely covered by equity research firms, and target prices are revealing. From a summary standpoint, we track the median one-year price target among 5 analysts covering the company at $1.00. That suggests shares of the stock may have another 67 percent to the upside left to run. Of those analysts we surveyed, the highest price target on recordsits at $3.00, which would imply another -709 percent in upside potential. If we look for a little more qualitative data on the range of expectations, we find in analyst notes that the stock has 2 “Buy” ratings in place. At the same time, 0 rate the stock a “strong buy”, suggesting more conviction in the story. As for the doubters, 3 equity research analyst firms call this stock a “Hold” and 0 consider it bad enough to warrant a “Sell” rating.
Analysts at Jefferies took a look at ANTH shares in a research note released on Dec 29, 2016, and issued a Hold rating to this company. Citigroup analysts provided their own take on company recently as well. In a research note published on Dec 29, 2016,the house assigned a Neutral rating to this stock. According to a piece that hit the wires on May 12, 2015, researchers at Citigroup reconsidered their prior rating on the stock, and upped it from Sell Perform to Neutral.
Anthera Pharmaceuticals, Inc. (ANTH) Cap Table Analysis
Breaking down the capitalization table is our next goal. From a bird’s eye view, Executives hold 1.95 percent of the stock.
If we take a more granular look, Dr. Christopher S. Henney, PhD is one of the largest owners in company capital stock among insiders. According to U.S. Securities and Exchange Commission (SEC) filings, this investor owns 202,429 shares, representing a total current market value of roughly $66801.57. Dr. Joaquim Trias, PhD is another major player among company insiders, currently holding 198,546 shares as of 1.98%, carrying a current market value of $65520.18. Christopher P. Lowe is currently ranked as the number three insider in terms of representation on the cap table for the stock, holding 108,915 shares, valued at around $35941.95 as of recent close.
We noted a few insider transactions for the stock recently as well.
In a transaction on 2015-11-13, the company’s Chief Medical Officer Hislop Colin sold 12,500 company shares for 66380. That means, once accounting for this transaction, the Chief Medical Officer is left with a stake of 21,044 shares, carrying a current total market value of $6945. In addition, by means of a transaction dated 2015-11-11, Chief Medical Officer Hislop Colin sold 5,000 shares worth $26900. After that transaction, this investor is left with a total holding of 21,044 shares, representing a total investment value of $6944.52. We also noted a 2015-10-12 transaction in which ANTH Chief Technology Officer ODINK DEBRA sold 1,205 shares at a stock price of $6.15, carrying a total value of $7410, after which, this insider’s investment stands at 21,751 shares, with an overall financial value of $7178.
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Earnings View
In the company’s last quarter, ANTH EPS moved to $ from $ compared sequentially with the prior quarter. Revenues for the company came in at $M. This stacks up against $M, on a sequential basis.
How does this compare with bottom and top-line expectations? Well, according to what we could find, analysts had been looking for the company to post net income of about $ per share on $M in revenue. That sets up an interesting next quarter report card. We would note that analysts seem to be projecting earnings, on average, for this quarter in the range of $-0.33 to $-0.13. On a year-over-year basis, that compares with an EPS comp of $.
ANTH, Anthera Pharmaceuticals, Inc., NASDAQ